Caphosol in Sarcoma Patients With Mucositis

Inclusion Criteria:

1. Patients with sarcoma which is locally advanced, at high risk for relapse or metastatic for whom treatment with high dose doxorubicin (75-90 mg/m\^2) with ifosfamide (AI) or cisplatin (AP) is indicated.
2. Must be \>16 and \< 65 years of age.
3. Females of childbearing potential (defined as not post-menopausal for 12 months, or no previous surgical sterilization) must have a negative blood pregnancy test.
4. Male and Females of child bearing potential must use acceptable methods of birth control which include oral contraceptives, spermicide with either a condom, diaphragm or cervical cap, us of a intrauterine device (IUD) or abstinence.
5. Adequate hematologic (ANC \> 1500/mm\^3, platelet count \> 150,000/mm\^3), renal (serum creatinine \< 1.5mg/dL), hepatic (serum bilirubin count \< 1.5 x normal and SGPT \<3 x normal) functions.
6. Karnofsky Performance Status \>/= 80%
7. Signed informed consent form.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Patients with any co-morbid condition which renders patients at high risk of treatment complication.
3. Patient has uncontrolled angina, congestive heart failure (New York Heart Association \> class II or known ejection fraction \< 40%), uncontrolled cardiac arrhythmia or hypertension, acute myocardial infarction within 3 months
4. Patient has an active seizure disorder. (Patients with a previous history of seizure disorders will be eligible for the study, if they have had no evidence of seizure activity, and they have been free of antiseizure medication for the previous 5 years.)
5. Prior surgery or radiotherapy (RT) within 2 weeks of study entry.
6. Psychological, social, familial, or geographical reasons that would prevent scheduled visits and follow-up.